Priothera
  • Home
  • About Us
  • Science
    • Our Clinical Candidate
    • Hematopoietic Stem Cell Transplantation
    • Our Pipeline
    • CAR T cell therapy
  • Publications
  • News
  • ESG
  • Contact Us
Select Page

S1P Receptor-1 agonist averts the De Novo Generation of Autoreactive T-cells in Murine Acute GVHD

https://priothera.com/wp-content/uploads/2021/11/new-publication-hs9-5-e613.pdf

Short-term KRP203 and posttransplant cyclophosphamide for graft-versus-host disease prophylaxis

https://priothera.com/wp-content/uploads/2020/09/Publication1.pdf

Recent Posts

  • Priothera – US FDA grants Orphan Drug Designation to mocravimod to improve the outcome of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in patients with hematologic malignancies
  • Priothera cleared to begin Japanese arm of pivotal Phase 3 study with mocravimod in patients with Acute Myeloid Leukemia undergoing allogeneic Hematopoietic Cell Transplant
  • Priothera announces first patients enrolled in pivotal MO-TRANS global Phase 2b/3 study with mocravimod as an adjunctive and maintenance therapy for patients with Acute Myeloid Leukemia (AML) undergoing allogeneic Hematopoietic Cell Transplant (HCT)
  • Priothera – Positive mocravimod Phase 1b clinical data published in Transplantation and Cellular Therapy
  • Priothera – Clinical Mocravimod Data in Hematological Malignancies Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant (aHSCT) Presented at the 2022 European Hematology Association (EHA) Congress

Recent Comments

    Contact Us

    Priothera Ltd

    88 Harcourt Street, Dublin 2,
    D02 DK18, Ireland

    Priothera SAS France

    57 Avenue Général de Gaulle
    68300 Saint-Louis, France

    

    © Priothera Ltd. 2023